Nkgen Biotech Korea
NKGen Biotech Korea Co Ltd is a South Korean clinical-stage biotechnology company developing natural killer (NK) cell therapies for neurodegenerative diseases and oncology. The company advances its proprietary SNK autologous and allogeneic NK cell therapy platform, focusing on clinical trials for Alzheimer's disease, Parkinson's disease, and advanced solid tumors. Main revenue drivers currently consist of investment capital financing, research partnership grants, and development milestone fees as clinical pipeline trials advance. NKGen Biotech Korea targets neurologists, medical oncologists, clinical trial research centers, and biopharmaceutical partners across South Korea and North America. The company holds an innovative position in cell therapy research for neurodegenerative conditions and immuno-oncology. Headquartered in Seoul, South Korea, it operates as a biotechnology research enterprise.
2 of the funds FundTelligence covers report a position in Nkgen Biotech Korea.
- Legal name
- Nkgen Biotech Korea Co Ltd
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 2
Funds holding Nkgen Biotech Korea
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)